A SOX10+/AR- immunoprofile may identify a subset of low positive ER carcinomas with a wider range of ER expression
Pathology - Research and Practice · 2023
DOI: 10.1016/j.prp.2023.154628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2023. Verfasst von Aysenur Keske und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Electronic address: …. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: Department of Laboratory Medicine and Pathology, University of Washington, University of Wisconsin Madison Department of Pathology and Laboratory Medicine.
Abstract (Originalsprache)
BACKGROUND: Invasive breast carcinomas (IBC) that strongly express SOX10 are almost always negative for androgen receptor (AR). Furthermore, this SOX10+/AR- subset of IBC is nearly always estrogen receptor and progesterone receptor negative (ER-/PR-), being most commonly seen in triple negative breast carcinomas (TNBC), but also in a small subset of HER2+/ER-/PR- IBC. Following our previous work demonstrating the expression of SOX10 in a subset of IBC with "low positive" ER expression (i.e. 1-10 % ER+ staining based on CAP guidelines, here referred to as "ER-low"), we sought to investigate the expression of both SOX10 and AR in a larger cohort of ER-low tumors. As our previous work also revealed occasional SOX10 expression in IBC with >10 % ER+ staining, we also included tumors with any percentage of ER staining, as long as the staining intensity was weak (this subset is referred to as "ER-weak"). METHODS: We screened cases of HER2-/ER+ IBC diagnosed at our institution over a 10 year period, identified both ER-low and ER-weak tumors and stained both groups with SOX10 and AR. RESULTS: Strong SOX10 expression was seen in 12/25 (48 %) ER-low tumors and 13/24 (54 %) ER-weak tumors. ER staining in the SOX10+ subset of ER-weak tumors ranged from 15 %-80 % (median 25 %). As expected, AR was negative in all but 1 of the SOX10+ tumors in both groups. While case numbers in these groups were too small for a meaningful statistical analysis, we did note that all SOX10+/AR- tumors within both the ER-low and ER-weak groups were histologic grade 3. CONCLUSION: The presence of a SOX10+/AR- profile in a significant subset of ER-low tumors confirms the findings of our previous work and provides further support for the proposed functionally ER negative status of this group. Furthermore, the fact that the same SOX10+/AR- profile is seen in a roughly equal subset of ER-weak tumors suggests that a wider range of ER staining may be acceptable as "low positive" in SOX10+/AR- tumors, as long as the ER staining is of weak intensity. However, given the small number of cases in this single institution study, we emphasize the need for larger studies to establish the biological and clinical significance of this tumor subset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Electronic address: akeske@uwhealth.org.
- Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Sanford Health, Fargo, ND, USA.
- Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
- Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
- Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, 600 Highland Ave, Madison, WI 53792-3224, USA.
Förderung
- Department of Laboratory Medicine and Pathology, University of Washington
- University of Wisconsin Madison Department of Pathology and Laboratory Medicine
Zitieren
APA
Keske, A., Shetty, S., Weisman, P., Yu, Q., McGregor, S. M., & Xu, J. (2023). A SOX10+/AR- immunoprofile may identify a subset of low positive ER carcinomas with a wider range of ER expression. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2023.154628
Vancouver
Keske A, Shetty S, Weisman P, Yu Q, McGregor SM, Xu J. A SOX10+/AR- immunoprofile may identify a subset of low positive ER carcinomas with a wider range of ER expression. Pathology - Research and Practice. 2023. doi:10.1016/j.prp.2023.154628
BibTeX
@article{Keske2023,
author = {Keske, Aysenur and Shetty, Sindhu and Weisman, Paul and Yu, Qiqi and McGregor, Stephanie M and Xu, Jin},
title = {A SOX10+/AR- immunoprofile may identify a subset of low positive ER carcinomas with a wider range of ER expression},
journal = {Pathology - Research and Practice},
year = {2023},
doi = {10.1016/j.prp.2023.154628}
}
EUVIMED